Reversible effects of sodium butyrate on the differentiation of F9 embryonal carcinoma cells.
We have studied effects of sodium butyrate on embryonal carcinoma F9 cell differentiation. In the presence of sodium butyrate, F9 cells underwent rapid and drastic morphological changes and expressed marked increases in mRNA levels of various differentiation markers. When sodium butyrate was removed from the cultures, all the examined phenotypes of F9 cell differentiation rapidly reverted to the characteristics of undifferentiated stem cells. However, under the same conditions, when cycloheximide or actinomycin D was added to the cultures, such phenotypic reversion was not observed, but high mRNA levels of the differentiation markers as well as altered cell morphology were retained. These results indicated that the effects of sodium butyrate on induction of teratocarcinoma cell differentiation were reversible and that de novo syntheses of some mRNA(s) and protein(s) were necessary for the reversion of differentiated cells to stem cells.
Kosaka
M
M
Research Institute for Microbial Diseases, Osaka University, Japan.
Nishina
Y
Y
Takeda
M
M
Matsumoto
K
K
Nishimune
Y
Y
D000818:Animals; D000943:Antigens, Differentiation / Q000235:genetics; D014408:Biomarkers, Tumor / Q000235:genetics; D002087:Butyrates / Q000494:pharmacology*; D020148:Butyric Acid; D002454:Cell Differentiation / Q000187:drug effects; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D054278:Embryonal Carcinoma Stem Cells; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D066298:In Vitro Techniques; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000187:drug effects*; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics; D010959:Tissue Plasminogen Activator / Q000096:biosynthesis / Q000235:genetics
D000943:Antigens, Differentiation; D014408:Biomarkers, Tumor; D002087:Butyrates; D016271:Proto-Oncogene Proteins c-myc; D020148:Butyric Acid; D003609:Dactinomycin; D003513:Cycloheximide; D010959:Tissue Plasminogen Activator